ReviewCancers2023
Recurrent Differentiated Thyroid Cancer: The Current Treatment Options.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Synergistic role of molecular imaging and genomics in thyroid cancer management: from diagnosis to personalized treatment.Journal of translational medicine · 2026Review
- Mechanistic and Clinical Perspectives on Traditional Chinese Medicine in Thyroid Cancer Management.Biomolecules & therapeutics · 2026Review
- Moderate- versus high-activity radioactive iodine in intermediate-risk papillary thyroid cancer: a Canadian cohort study.Journal of the Endocrine Society · 2026Article
- A predictive nomogram for progression-free survival in radioiodine-refractory papillary thyroid carcinoma after reoperation: a longitudinal study in Vietnam.Endocrine journal · 2026Article
- Prognostic Comparison of Long-Term Outcomes and Nodal Recurrence for Persistent and Recurrent Differentiated Thyroid Cancer.Clinical and experimental otorhinolaryngology · 2026Article
- Limited effectiveness of radioiodine therapy for residual cervical lymph node metastases in radioiodine-naïve papillary thyroid cancer.Frontiers in endocrinology · 2026Article
- Explaining Risk Stratification in Differentiated Thyroid Cancer Using SHAP and Machine Learning Approaches.Biomedicines · 2025Article
- Diagnostic Challenges, Prognostic Assessment, and Treatment Strategies in High-Grade Differentiated Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- Psychological distress in thyroid cancer patients: Influencing factors and intervention strategies.World journal of clinical oncology · 2025Review
- BRAF V600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression.Endocrine connections · 2025Article
- Evolving Paradigm in Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Historical Perspectives, Current Practices and Future Directions.Diagnostics (Basel, Switzerland) · 2025Review
- Long-Term Results of External Beam Radiation Therapy with or Without Concurrent Chemotherapy in Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2025Article
- Associations between pathological features and radioactive iodine-refractory recurrent papillary thyroid carcinoma: with mutation analysis using recurrent samples.BMC endocrine disorders · 2025Article
- The Current Understanding of the Molecular Pathogenesis of Papillary Thyroid Cancer.International journal of molecular sciences · 2025Review
- Analysis of Tryptophan Metabolic Profile Characteristics and Clinical Value in Differentiated Thyroid Cancer Patients.Cancer medicine · 2025Article
- Efficacy and Safety of Pazopanib in the Treatment of Thyroid Cancer: A Systematic Review.Biomedicines · 2024Review
- Effective Preparation of FFPE Tissue Samples for Preserving Appropriate Nucleic Acid Quality for Genomic Analysis in Thyroid Carcinoma.Endocrine pathology · 2024Article
- Treatment outcomes in patients with papillary thyroid cancer undergoing radiofrequency ablation of metastatic lymph nodes.Gland surgery · 2024Article
- Aggressive Types of Malignant Thyroid Neoplasms.Journal of clinical medicine · 2024Review
- Safety and Effectiveness of Percutaneous Ethanol Injection as a Treatment for Locally Recurrent Papillary Thyroid Carcinoma.International journal of endocrinology and metabolism · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Differentiated thyroid carcinomas (DTC) have an excellent prognosis, but this is sometimes overshadowed by tumor recurrences following initial treatment (approximately 15% of cases during follow-up), due to unrecognized disease extent at initial diagnosis or a more aggressive tumor biology, which are the usual risk factors. The possible sites of recurrence are local, regional, or distant. Local and regional recurrences can usually be successfully managed with surgery and radioiodine therapy, as are some isolated distant recurrences, such as bone metastases. If these treatments are not possible, other therapeutic options such as external beam radiation therapy or systemic treatments should be considered. Major advances in systemic treatments have led to improved progression-free survival in patients previously considered for palliative treatments; among these treatments, the most promising results have been achieved with tyrosine kinase inhibitors (TKI). This review attempts to give a comprehensive overview of the current treatment options suited for recurrences and the new treatments that are available in cases where salvage surgery is not possible or in cases resistant to radioiodine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.